Atle Fund Management AB Raises Stake in NewAmsterdam Pharma Company N.V. $NAMS

Atle Fund Management AB grew its position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 23.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 193,625 shares of the company’s stock after purchasing an additional 36,402 shares during the quarter. NewAmsterdam Pharma makes up about 2.2% of Atle Fund Management AB’s investment portfolio, making the stock its 17th largest holding. Atle Fund Management AB’s holdings in NewAmsterdam Pharma were worth $5,507,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Frazier Life Sciences Management L.P. lifted its stake in shares of NewAmsterdam Pharma by 3.0% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock valued at $300,754,000 after buying an additional 490,656 shares in the last quarter. Jennison Associates LLC increased its stake in NewAmsterdam Pharma by 42.5% in the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after buying an additional 1,252,451 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in NewAmsterdam Pharma by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after acquiring an additional 1,062,359 shares during the period. Alliancebernstein L.P. lifted its position in shares of NewAmsterdam Pharma by 4.0% in the second quarter. Alliancebernstein L.P. now owns 2,331,583 shares of the company’s stock valued at $42,225,000 after acquiring an additional 89,630 shares in the last quarter. Finally, Maverick Capital Ltd. lifted its position in shares of NewAmsterdam Pharma by 178.8% in the second quarter. Maverick Capital Ltd. now owns 1,531,874 shares of the company’s stock valued at $27,742,000 after acquiring an additional 982,405 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

NAMS has been the subject of several research analyst reports. Leerink Partners reiterated an “outperform” rating and set a $55.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. Citigroup increased their price objective on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. Stifel Nicolaus lifted their price objective on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. The Goldman Sachs Group upped their target price on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a research report on Tuesday, December 2nd. Finally, Royal Bank Of Canada raised their target price on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $47.00.

NewAmsterdam Pharma Price Performance

Shares of NAMS opened at $31.12 on Friday. The stock has a market capitalization of $3.53 billion, a price-to-earnings ratio of -15.18 and a beta of 0.07. NewAmsterdam Pharma Company N.V. has a 1 year low of $14.06 and a 1 year high of $42.00. The business’s 50 day simple moving average is $35.05 and its 200-day simple moving average is $31.38.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). The business had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $4.54 million. NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. On average, sell-side analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Insider Transactions at NewAmsterdam Pharma

In related news, insider Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $33.25, for a total value of $199,500.00. Following the completion of the transaction, the insider owned 73,481 shares in the company, valued at approximately $2,443,243.25. This trade represents a 7.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Louise Frederika Kooij sold 32,612 shares of the company’s stock in a transaction that occurred on Wednesday, January 28th. The shares were sold at an average price of $31.80, for a total value of $1,037,061.60. Following the sale, the chief accounting officer owned 24,353 shares in the company, valued at approximately $774,425.40. This trade represents a 57.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 298,647 shares of company stock worth $10,236,050. Insiders own 20.84% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.